Junping Shi

Years Active: 2019-2020
Publications (10 Years): 5

OrigiMed

This page only lists publications with an associated author ORCID identifier.

Affiliation History

OrigiMed Sep 12 2016

China

Medical Adviser :: Medical Department

Publications

Wei Zhang, Junping Shi, Rentao Li, Zhiqiang Han, Ling Li, Guanghao Li, Bo Yang, Qiang Yin, Yingying Wang, Yan Ke, Qiang Li
Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation. The oncologist 25 (5) (2020)
Xiaobo Yang, Junping Shi, Xiaoqian Chen, Yan Jiang, Haitao Zhao
Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression. The oncologist 25 (6) (2020)
Nan Zhang, Junping Shi, Xiaoliang Shi, Wenting Chen, Junfeng Liu
Mutational Characterization and Potential Prognostic Biomarkers of Chinese Patients with Esophageal Squamous Cell Carcinoma. OncoTargets and therapy 13 (2020)
Ran Huo, Jinghua Li, Xiaofang Li, Junping Shi, Kunjie Wang, Jin Jiao, Yanhong Shang
Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation. The oncologist 25 (10) (2020)
Yan Guan, Zhanshuai Song, Yan Li, Honglin Guo, Junping Shi, Xuemei Zhang, Ming Yao
Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion. The oncologist 24 (8) (2019)

Junping Shi.css-eqlu8i{font-size:small;padding-left:4px;}